LA JOLLA, Calif., January 3, 2013 Sanford-Burnham Medical Research Institute, a nonprofit research institution and one of the largest iPSC generators in the world, and Intrexon Corporation, a leading synthetic biology company, today announced a new collaboration to accelerate stem cell research. Under the agreement, Sanford-Burnham will gain access to sophisticated proprietary cellular selection and gene regulation technologies that are not currently on the market, including Intrexon's Laser-Enabled Analysis and Processing (LEAP) instrument and RheoSwitch Therapeutic System (RTS). As part of the agreement, Intrexon may obtain commercial and intellectual property rights resulting from technological advances made under the collaboration.
"I'm looking forward to merging and melding our expertise," said Evan Y. Snyder, M.D., Ph.D., professor and director of Sanford-Burnham's Stem Cell Research Center and Stem Cell and Regenerative Biology Program. "We'll bring our iPSC and gene therapy expertise to the table. Likewise, our colleagues at Intrexon will share their knowledge of how best to use the technologies. We envision we'll be meeting with them frequently and sharing insights to further advance the platforms for stem cell applications."
Sanford-Burnham is currently building the world's largest collection of human iPSCs generated from individual patients and healthy volunteers. The Stem Cell Research Center's expertise and resources are available to all Sanford-Burnham scientists, as well as other researchers at nonprofit and for-profit research organizations around the world.
LEAP for induced pluripotent stem cells
The LEAP instrument is an automated system that provides high-throughput cell imaging coupled with versatile laser-based cell processing. The instrument's applications include rapid and accurate in situ purification of adherent cells and cell colonies, features that are particu
|Contact: Heather Buschman|
Sanford-Burnham Medical Research Institute